XPO1 and acute myeloid leukemia: Here, through multi-omics and functional approaches in primary AML patient samples and human cellular models, we observed a strong and selective sensitivity to XPO1 inhibition of t(6;9) cells and demonstrated that DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia drivers.